Pharma Companies Performance: Three Chinese pharmaceutical companies, SINO BIOPHARM, HANSOH PHARMA, and CMS, reported strong results for the first half of 2025, achieving double-digit revenue growth.
Future Growth Projections: CLSA forecasts that the positive momentum will continue into the second half of 2025, driven by new drug launches, increased sales, favorable healthcare spending, and potential business development revenue.
Broker Ratings and Target Prices: CLSA maintained an Outperform rating for SINO BIOPHARM with a target price of HKD9.2, while also raising target prices for HANSOH PHARMA from HKD27.8 to HKD43.1 and for CMS from HKD10 to HKD15.6.
Short Selling Data: As of August 20, 2025, short selling figures indicate significant activity in these stocks, with HANSOH PHARMA having the highest short selling ratio at 45.051%.
00867
$13.4+Infinity%1D
Analyst Views on 00867
Wall Street analysts forecast 00867 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00867 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 00867 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00867 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 13.400
Low
Averages
High
Current: 13.400
Low
Averages
High
CLSA
CLSA
Outperform
maintain
2025-08-20
Reason
CLSA
CLSA
Price Target
2025-08-20
maintain
Outperform
Reason
The analyst rating for the three Chinese pharma companies—SINO BIOPHARM, HANSOH PHARMA, and CMS—was based on their solid results for the first half of 2025, which included double-digit revenue growth. The research report by CLSA highlighted that this positive momentum is expected to continue into the second half of 2025 due to several favorable factors: the launch of more innovative drugs, increased sales of new products, a more favorable environment for Chinese healthcare insurance spending, and potential business development revenue. As a result, CLSA reiterated an Outperform rating for all three companies, with target prices adjusted accordingly.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
